ANDA Abbreviated New Drug Application BY N.NARESH KUMAR m.pharm(cology) Definition of ANDA:  AN “abbreviated new drug application” (ANDA) is an application for a US…

1. ELECTROLYTE DYSBALANCE IN CHF: PROGNOSIS & MANAGEMENT Dr. Arindam Pande, MD, DM Associate Consultant, Cardiology Apollo Gleneagles Hospital, Kolkata 2. PATHOPHYSIOLOGY…

1. CardiacResynchronisationTherapy September 2008 2. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure (CARE-HF) John G.F. Cleland, M.D.,…

1. CardiacResynchronisationTherapy September 2008 2. The Effect of Cardiac Resynchronization on Morbidity and Mortality in Heart Failure (CARE-HF) John G.F. Cleland, M.D.,…

1. Progressive Resistance Training Use in Cardiovascular Disease andSafety Considerations Professor Maria A. Fiatarone Singh, MD, FRACP 2. Introduction and Background Progressive…

Slide 1Simonetta Scalvini, MD Head of Telemedicine Unit IRCCS Salvatore Maugeri Foundation Lumezzane (BS) - Italy OPEN DAYS - Bruxelles, 9th October 2008 Realized Benefits…

Slide 1First International Conference on Evidence- based healthcare (Pre-Conference Workshops on Topics related to Evidence Based Medicine) The Inaugural Conference of the…

Slide 1Sharp HospiceCares Transitions Program A New Model for Late Stage Disease Management Daniel R. Hoefer, MD CMO, Outpatient Palliative Care and Hospice Suzi K. Johnson,…

Slide 1Susan Schow, MPH Epidemiologist Maine Health Data Organization March 30, 2010 Heart Failure Readmission Reduction Project & Summit Slide 2 Heart Failure Readmission…

Slide 1SEPONL April 4 th, 2014 A Patient & Family Discharge Planning Model that Works Slide 2 Or, Goodbyes Matter How can we ensure a “Good Fit” when we say Good-bye?…